Get access

Rescue therapy with high-dose oral phenobarbitone loading for refractory status epilepticus

Authors


Assistant Professor Jo Wilmshurst, Department of Paediatric Neurology, Red Cross Children's Hospital, Rondebosch, Cape Town, 7700, South Africa. Fax: +27 21 689 1287; email: jo.wilmshurst@uct.ac.za

Abstract

Aim:  Parenteral phenobarbitone was unavailable in South Africa from 2005 to 2006. This study aimed to establish the effectiveness of enteral phenobarbitone in the management of childhood status epilepticus.

Method:  Patients in status epilepticus (December 2005–June 2006) received 20 mg/kg phenobarbitone via nasogastric tube in addition to standard status interventions (benzodiazepine boluses, phenytoin infusion). Phenobarbitone concentrations were taken post loading. Phenobarbitone population pharmacokinetics was analysed using non-linear mixed effects modelling.

Results:  Sixteen patients (7 female, 9 male) were assessed, median age 5 months (range 9 days–168 months). Nine patients received 20 mg/kg; the maximum total dosage administered was 80 mg/kg with a concentration of 283 µmol/L. The typical population value of the volume of distribution was 1.2 (95% confidence interval (CI): 0.8–1.6) L/kg with interindividual variability (as coefficient of variation) of 53% (95% CI, 9–74%). Seizure control was documented within 1 h (n= 8), 11/2 h (n= 1), 3 h (n= 1) and 4 h (n= 5) following enteral phenobarbitone loading. No adverse effects were apparent from the enteral phenobarbitone administration.

Conclusion:  Patients tolerated enteral loading with phenobarbitone. A single enteral loading dose resulted in adequate phenobarbitone exposure. This practice was a safe intervention for centres lacking parenteral phenobarbitone. Therapeutic concentrations and seizure control after enteral loading suggested a role for enteral phenobarbitone in the management of acute status epilepticus as well as prophylaxis against seizure recurrence.

Ancillary